8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
Mar 26, 2026·SEC
Gain Therapeutics, Inc.(GANX)Earnings, Financials & Key Ratios
GANX•NASDAQ
$1.81
Price updated Jul 6, 2026
AboutGain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.Show more
- Revenue$0
- EBITDA-$19M+8.1%
- Net Income-$20M+1.2%
- EPS (Diluted)-0.61+31.5%
- ROE-155.66%+24.1%
GANX Price & Volume
Gain Therapeutics, Inc. (GANX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
Key Thesis Takeaways
- Gain Therapeutics remains a pre-revenue, development-stage biotechnology firm whose valuation is entirely contingent on the successful validation of its SEE-Tx platform.
- While the company maintains a low debt-to-equity ratio of 0.04, the persistent quarterly operating losses, which reached $5.4 million in 2026Q1, necessitate ongoing reliance on external financing.
- Investors should monitor the company's ability to extend its $20.8 million cash position from 2025Q4, as the lack of commercial revenue streams creates significant dilution risk for existing shareholders.
Verdict Logic
the company's inability to generate revenue against a $101.4 million accumulated deficit in retained earnings suggests that the current $20.8 million cash position may be insufficient to support long-term clinical development without further dilutive events.
GANX Growth Metrics
Gain Therapeutics, Inc. (GANX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-1.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM34.83%
Return on Capital
10 Years-975.88%
5 Years-115.92%
3 Years-151.2%
Last Year-135.2%
GANX Recent Earnings
Gain Therapeutics, Inc. (GANX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
—
$33,333
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.11+21.4%
$0.14
Rev
—
$25,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.15+0.0%
$0.15
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.19-11.8%
$0.17
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.13vs $0.13+0.0% | —vs $33,333 |
| Q2 2026 | Mar 26, 2026 | $0.11vs $0.14+21.4% | —vs $25,000 |
| Q4 2025 | Nov 12, 2025 | $0.15vs $0.15+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.19vs $0.17-11.8% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Gain Therapeutics, Inc. (GANX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.81 | $77.2M | -2.97 | — | — | -155.66% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $98.52 | $6.52B | 71.91 | 15.24% | 9.48% | 5.13% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $320.42 | $6.42B | 52.27 | 60.4% | 55.95% | 16.19% | — |
Compare GANX vs Peers
Gain Therapeutics, Inc. (GANX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GANX SEC Filings & Documents
Gain Therapeutics, Inc. (GANX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GANX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GANX Frequently Asked Questions
Gain Therapeutics, Inc. (GANX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is GANX profitable?
Gain Therapeutics, Inc. (GANX) reported a net loss of $21.2M for fiscal year 2025.
Dividend & Returns
What is GANX's return on equity?
Gain Therapeutics, Inc. (GANX) has a return on equity (ROE) of -155.7%. Negative ROE indicates the company is unprofitable.
What is Gain Therapeutics, Inc.'s free cash flow?
Gain Therapeutics, Inc. (GANX) had negative free cash flow of $19.4M in fiscal year 2025, likely due to heavy capital investments.